Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 5 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Gilgamesh Pharmaceuticals Inc. maintains 6 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 6 distinct examiners, resulting in a one-to-one ratio of pending actions to examiners. This broad distribution of personnel is accompanied by a wide technical spread, as the applications are situated across 5 distinct art units. Such a distribution indicates that the company's research covers a diverse range of specific sub-disciplines within the broader Biotechnology & Pharmaceuticals sector.
The busiest examiner for the company is REILLY, SOPHIA JANE, who is currently managing 1 pending office action. This workload matches the 1 pending action assigned to every other examiner involved with the portfolio. The presence of 5 distinct art units for only 6 pending actions suggests that almost every application is being treated as a unique technical category by the patent office. This high degree of variety across both examiners and art units requires a versatile approach to managing the current prosecution pipeline.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (17%) |
| Double-patenting only | 1 (17%) |
| Double-patenting + other | 2 (33%) |
| Multi-statute (no §101) | 2 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REILLY, SOPHIA JANE | 1 | 60.8% | +49.2% |
| RZECZYCKI, PHILLIP MATTHEW | 1 | 64.8% | +37.0% |
| KLINKEL, KORTNEY L | 1 | 39.8% | +43.1% |
| VALLE, ERNESTO | 1 | 65.8% | +32.9% |
| ANDERSON, REBECCA L | 1 | 73.4% | +23.6% |
| COPPINS, JANET L | 1 | 72.6% | +26.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18686059 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | RZECZYCKI, PHILLIP MATTHEW | — |
| 18281127 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | ANDERSON, REBECCA L | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18857979 | PYRIDINE DERIVATIVES FOR TREATING PSYCHIATRIC DISORDERS | REILLY, SOPHIA JANE | — |
| 18686059 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | RZECZYCKI, PHILLIP MATTHEW | — |
| 18572861 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | KLINKEL, KORTNEY L | — |
| 18287980 | NOVEL ERGOLINES AND METHODS OF TREATING MOOD DISORDERS | VALLE, ERNESTO | — |
| 18281127 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | ANDERSON, REBECCA L | — |
| 17714879 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | COPPINS, JANET L | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| 1627 | 1 |
| 1623 | 1 |
| 1626 | 1 |
| 1628 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18857979 | PYRIDINE DERIVATIVES FOR TREATING PSYCHIATRIC DISORDERS | REILLY, SOPHIA JANE | — | §102§103§112DP | Non-Final OA | — | Pending | Oct 18, 2024 |
| 18686059 | COMBINATIONS OF PERIPHERAL 5-HT2A RECEPTOR ANTAGONISTS AND CENTRAL 5-HT2A RECEPTOR AGONISTS | RZECZYCKI, PHILLIP MATTHEW | 1625 | §103§112 | Non-Final OA | — | Pending | Feb 23, 2024 |
| 18572861 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | KLINKEL, KORTNEY L | 1627 | §102Other | Non-Final OA | — | Pending | Dec 21, 2023 |
| 18287980 | NOVEL ERGOLINES AND METHODS OF TREATING MOOD DISORDERS | VALLE, ERNESTO | 1623 | DP | Non-Final OA | — | Pending | Oct 23, 2023 |
| 18281127 | PHENALKYLAMINES AND METHODS OF MAKING AND USING THE SAME | ANDERSON, REBECCA L | 1626 | §102§103 | Non-Final OA | — | Pending | Sep 08, 2023 |
| 17714879 | ARYLCYCLOHEXYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS | COPPINS, JANET L | 1628 | §112DP | Final Rejection | — | Pending | Apr 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial